PharmacoEconomics

, Volume 1, Issue 2, pp 103–115 | Cite as

Pharmacoeconomics of Intravenous Drug Administration

  • S. E. Parker
  • P. G. Davey
Review Article

Summary

Direct administration of a drug into a vein guarantees bioavailability, i.e. the total amount of drug is fully available to the bloodstream for transport to all areas of the body. What is not ensured is the safety, need and ‘Value for money’ of this route. Few workers would disagree that there is increased morbidity associated with this method of administration. Adverse events range from the painful irritation of veins to life-threatening infection introduced by needle puncture. It is proposed that in many situations the disadvantages of the intravenous (IV) route outweigh the advantages.

There are many hidden costs of IV therapy ranging from the adverse events associated with IV administration to the need for specialised equipment, consumables and additional personnel time. Recent studies have shown that the oral route can be substituted in many patients receiving IV therapy without loss of efficacy. The reduction in costs intrinsic to IV therapy is an additional bonus.

There is a need to increase the use of alternative routes of administration on the basis of safety, quality of life and cost.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allcutt DA, Lort D, McCollum CN. Final inline filtration for intravenous infusions. A prospective hospital study. British Journal of Surgery 70: 111–113, 1983PubMedCrossRefGoogle Scholar
  2. Backhouse CM, Ball PR, Booth S, Kelshaw MA, Potter SR, et al. Particulate contaminants of intravenous medications and infusions. Journal of Pharmacy and Pharmacology 39: 241–245, 1987PubMedCrossRefGoogle Scholar
  3. Baciewicz AM. Conversion of intravenous ranitidine to oral therapy. Drug Intelligence and Clinical Pharmacy 25: 251–252, 1991Google Scholar
  4. Bakker-Woudenberg IAJM, Roosendaal R. Impact of dosage regimens on the efficacy of antibiotics in the immunocompromised host. Journal of Antimicrobial Chemotherapy 21: 145–150, 1988PubMedCrossRefGoogle Scholar
  5. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient parenteral antibiotics. A review of the literature. American Journal of Medicine 87: 301–305, 1989PubMedCrossRefGoogle Scholar
  6. Bioavailability and bioequivalence requirements rules and regulations. Federal Register 42: 1643, 1977Google Scholar
  7. Breckenridge A. Report of the working party on the addition of drugs to intravenous fluids. DHSS, Health Circular HC (76) March 9, 1976Google Scholar
  8. Clark CM, Bailie GR, Whitaker AM, Goldberg LA. Parenteral drug delivery — value for money? Pharmaceutical Journal 236: 453–455, 1986Google Scholar
  9. Clark C. Centralised IV additive services — better control for pharmacies? British Journal of Pharmaceutical Practice 10: 502–504, 1988Google Scholar
  10. Coleman RW, Rondoni LC, Kaubisch S, Granzella NB, O’Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control. Experience at the Palo Alto Veterans Affairs Medical Center 1987 to 1989. American Journal of Medicine 90: 439–444, 1991PubMedGoogle Scholar
  11. Cousins DH, Lee M, Stanaway M, Neary C. Implementation and evaluation of a centralised IV additive service for antibiotic injections. Pharmaceutical Journal 242 (Hospital Suppl): 14–16, 1989Google Scholar
  12. Dannenhoffer MA, Slaughter RL, Hunt SN. Use of concurrent monitoring and a preprinted note to modify prescribing of IV cimetidine and ranitidine in a teaching hospital. American Journal of Hospital Pharmacy 46: 1570–1575, 1989PubMedGoogle Scholar
  13. Davey P, Malek M. Pharmacoeconomics of antibacterial treatment. Current Opinion in Infectious Diseases 3: 780–785, 1990CrossRefGoogle Scholar
  14. Davey P, Dodd T, Kerr S, Malek M. Audit of IV antibiotic administration. Pharmaceutical Journal 244: 793–796, 1990Google Scholar
  15. Davey PG, Parker SE. Cost effectiveness of once daily oral antimicrobial therapy. American Journal of Clinical Pharmacology, in press, 1992Google Scholar
  16. Denton M, Morgan MS, White RR. Quality of prescribing of intravenous antibiotics in a district general hospital. British Medical Journal 302: 327–328, 1991PubMedCrossRefGoogle Scholar
  17. Donnelly EB, Witte KW, Eck TA, LaPlume G. Interdisciplinary committee on infusion-control devices. Containing related-product costs. American Journal of Hospital Pharmacy 45: 595–600, 1988PubMedGoogle Scholar
  18. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrobial Agents and Chemotherapy 32: 289–297, 1988PubMedCrossRefGoogle Scholar
  19. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, et al. What is the cost of nephrotoxicity associated with aminogly-cosides? Annals of Internal Medicine 107: 900–909, 1987PubMedGoogle Scholar
  20. Falchuk KH, Peterson L, McNeil BJ. Microparticulate-induced phlebitis. New England Journal of Medicine 312: 78–82, 1985PubMedCrossRefGoogle Scholar
  21. Fass RJ. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. American Journal of Medicine 82 (Suppl. 4A): 202–207, 1987PubMedGoogle Scholar
  22. Harvey KJ, Stewart R, Hemming M, Naismith N, Moulds RFW. Educational antibiotic advertising. Medical Journal of Australia 145: 28–32, 1986PubMedGoogle Scholar
  23. Himmelberg CJ, Pleasants RA, Weber DJ, Kessler JM, Samsa GP, et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. American Journal of Hospital Pharmacy 48: 1220–1227, 1991PubMedGoogle Scholar
  24. Hodson ME, Roberts CM, Butland RJA, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1: 235–237, 1987PubMedCrossRefGoogle Scholar
  25. Jewesson PJ, Bachand RL, Bell GA, Ensom RJ, Chow AW. Quality of use of parenteral metronidazole therapy in a teaching hospital. Canadian Medical Association Journal 132: 785–789, 1985PubMedGoogle Scholar
  26. Johnson EJ, MacGowan AP, Potter MN, Stockley RJ, White LO, et al. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. Journal of Antimicrobial Chemotherapy 25: 837–842, 1990PubMedCrossRefGoogle Scholar
  27. Klastersky J, Daneau D, Swings G, Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. Journal of Infectious Diseases 129: 187–193, 1974PubMedCrossRefGoogle Scholar
  28. Larson E, Hargiss C. A decentralized approach to maintenance of intravenous therapy. American Journal of Infection Control 12: 177–186, 1984PubMedCrossRefGoogle Scholar
  29. Leigh DA. Economic implications of oral treatment replacing parenteral therapy. 6th Medical Congress of Chemotherapy, Taormina, May 22–27, 1988. pp. 189–197, 1988Google Scholar
  30. Li SC, Ioannides-Demos LL, Spicer WJ, Berbatis C, Spelman DW, et al. Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. Medical Journal of Australia 151: 224–230, 1989PubMedGoogle Scholar
  31. Mackenzie A, Barnes G. Randomised controlled trial comparing oral and intravenous rehydration therapy in children with diarrhoea. British Medical Journal 303: 393–396, 1991PubMedCrossRefGoogle Scholar
  32. Malek M, Lynch W, Wells N, Elliott T, Bint A, et al. A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals. Journal of Antimicrobial Therapy, in press, 1992Google Scholar
  33. McCue JD, Hansen C, Gal P. Hospital charges for antibiotics. Reviews of Infectious Diseases 7: 643–645, 1985PubMedCrossRefGoogle Scholar
  34. Neu HC. Antimicrobial agents. The old and the new. American Journal of Infection Control 17: 276–285, 1989PubMedCrossRefGoogle Scholar
  35. Newhouse JG, Paul VM, Waugh NA, Frye CB. Reducing IV waste to under 2.25 percent. Hospital Pharmacy 23: 241–247, 1988PubMedGoogle Scholar
  36. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Medical Journal of Australia 153: 516–518, 1990PubMedGoogle Scholar
  37. Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Sparks. Outpatient use of ceftriaxone. A cost-benefit analysis. American Journal of Medicine 77: 77–83, 1984PubMedCrossRefGoogle Scholar
  38. Powers T, Bingham DH. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. American Journal of Hospital Pharmacy 47: 1781–1784, 1990PubMedGoogle Scholar
  39. Quercia RA, Hills SW, Klimek JJ, McLaughlin JC, Nightingale CH, et al. Bacteriologic contamination of intravenous infusion delivery systems in an intensive care unit. American Journal of Medicine 80: 364–368, 1986PubMedCrossRefGoogle Scholar
  40. Quintilliani R, Cooper BW, Briceland LL, Nightingale CH. Economic impact of streamlining antibiotic administration. American Journal of Medicine 82 (Suppl. 4A): 391–394, 1987Google Scholar
  41. Ridgway E, Stewart K, Rai G, Kelsey MC, Bielawska C. The pharmacokinetics of cefuroxime axetil in the sick elderly patient. Journal of Antimicrobial Chemotherapy 27: 663–668, 1991PubMedCrossRefGoogle Scholar
  42. Riley MR, Cooke J. The planning, implementation and outcome of a change in intravenous nitrate prescribing strategy. International Journal of Pharmacy Practice 1: 30–33, 1991CrossRefGoogle Scholar
  43. Sandborn WJ, Forland SC, Cutler RE, Strong RM. Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. Journal of Clinical Pharmacology 30: 568–571, 1990PubMedGoogle Scholar
  44. Savitsky ME, Kirking DM, Cornish LA, Crudo DJ, Berardi RR. Costs associated with the inappropriate route of administration of parenteral histamine2-receptor antagonists. DICP: Annals of Pharmacotherapy 21: 885–889, 1987Google Scholar
  45. Smith AL. Oral antibiotic therapy for serious infections. Annual Review of Medicine 39: 171–184, 1988PubMedCrossRefGoogle Scholar
  46. Strandvik B, Hjelte L, Lingblad A, Ljundberg B, Malmborg A, et al. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scandinavian Journal of Infectious Diseases 60: 84–88, 1989PubMedGoogle Scholar
  47. Tomford W, Hershey CO, McLaren CE, Porter DK, Cohen DI. Intravenous therapy team and peripheral venous catheter-associated complications. Archives of Internal Medicine 144: 1191–1194, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • S. E. Parker
    • 1
  • P. G. Davey
    • 1
  1. 1.Departments of Pharmacology and Clinical PharmacologyNinewells Hospital and Medical SchoolDundeeScotland

Personalised recommendations